MCID: CRD137
MIFTS: 47

Cardiogenic Shock

Categories: Blood diseases, Cardiovascular diseases, Rare diseases

Aliases & Classifications for Cardiogenic Shock

MalaCards integrated aliases for Cardiogenic Shock:

Name: Cardiogenic Shock 58 62 32
Shock, Cardiogenic 71
Shock Cardiogenic 54

Characteristics:

Orphanet epidemiological data:

58
cardiogenic shock
Prevalence: 1-5/10000 (Europe);

Classifications:



External Ids:

ICD10 32 R57.0
ICD10 via Orphanet 33 R57.0
UMLS via Orphanet 72 C0036980
Orphanet 58 ORPHA97292
UMLS 71 C0036980

Summaries for Cardiogenic Shock

PubMed Health : 62 About cardiogenic shock: Cardiogenic (kar-dee-oh-JE-nik) shock is a condition in which a suddenly weakened heart isn't able to pump enough blood to meet the body's needs. The condition is a medical emergency and is fatal if not treated right away. The most common cause of cardiogenic shock is damage to the heart muscle from a severe heart attack. However, not everyone who has a heart attack has cardiogenic shock. In fact, on average, only about 7 percent of people who have heart attacks develop the condition. If cardiogenic shock does occur, it's very dangerous. When people die from heart attacks in hospitals, cardiogenic shock is the most common cause of death.

MalaCards based summary : Cardiogenic Shock, also known as shock, cardiogenic, is related to cardiac tamponade and atrioventricular block, and has symptoms including syncope and shock without mention of trauma. An important gene associated with Cardiogenic Shock is NPPB (Natriuretic Peptide B). The drugs Dalteparin and Tinzaparin have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and liver, and related phenotypes are reduced consciousness/confusion and dyspnea

Wikipedia : 74 Cardiogenic shock (CS) is a medical emergency resulting from inadequate blood flow due to the... more...

Related Diseases for Cardiogenic Shock

Diseases related to Cardiogenic Shock via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 418)
# Related Disease Score Top Affiliating Genes
1 cardiac tamponade 31.2 PLAT PIK3C2A NPPB CRP
2 atrioventricular block 30.9 PIK3C2A NPPB
3 myocardial infarction 30.8 PLAT PIK3C2A NPPB CRP ADM
4 acute myocarditis 30.8 NPPB CRP
5 mitral valve insufficiency 30.7 PIK3C2A NPPB CRP
6 pulmonary edema 30.6 PIK3C2A NPPB CRP
7 aortic valve insufficiency 30.6 NPPB CRP
8 mitral valve stenosis 30.5 NPPB CRP
9 ischemia 30.5 PLAT PIK3C2A NPPB
10 systolic heart failure 30.4 NPPB CRP
11 anterolateral myocardial infarction 30.4 PLAT NPPB
12 tricuspid valve insufficiency 30.3 NPPB CRP
13 toxic myocarditis 30.2 PIK3C2A NPPB
14 heart valve disease 30.1 NPPB CRP
15 coronary stenosis 30.1 PIK3C2A NPPB CRP
16 congestive heart failure 30.1 PIK3C2A NPPB CRP ADM
17 inferior myocardial infarction 30.1 PLAT PIK3C2A NPPB
18 cardiac rupture 30.0 PLAT CRP
19 coronary thrombosis 30.0 PLAT CRP
20 peripheral artery disease 30.0 NPPB CRP
21 kidney disease 30.0 NPPB CRP ADM
22 pericardial effusion 29.9 PIK3C2A NPPB CRP
23 exanthem 29.9 PIK3C2A CRP
24 anuria 29.9 PIK3C2A CRP
25 aortic valve disease 2 29.9 NPPB CRP
26 respiratory failure 29.9 PIK3C2A NPPB CRP ADM
27 pulmonary embolism 29.9 PLAT NPPB CRP
28 malignant hypertension 29.8 NPPB ADM
29 leptospirosis 29.8 PIK3C2A CRP
30 acute myocardial infarction 29.8 PLAT PIK3C2A NPPB CRP ADM
31 chronic thromboembolic pulmonary hypertension 29.8 NPPB CRP
32 renovascular hypertension 29.8 NPPB ADM
33 first-degree atrioventricular block 29.8 NPPB CRP
34 constrictive pericarditis 29.8 NPPB CRP
35 intermediate coronary syndrome 29.8 PLAT PIK3C2A CRP
36 kawasaki disease 29.8 NPPB CRP ADM
37 orbital plasma cell granuloma 29.7 PIK3C2A CRP
38 endocarditis 29.7 PLAT PIK3C2A CRP
39 left bundle branch hemiblock 29.7 PIK3C2A NPPB CRP
40 pericarditis 29.7 PIK3C2A NPPB CRP
41 compartment syndrome 29.7 PIK3C2A CRP
42 necrotizing fasciitis 29.7 PIK3C2A CRP
43 antiphospholipid syndrome 29.7 PLAT CRP
44 vascular disease 29.6 PLAT NPPB CRP
45 patent ductus arteriosus 1 29.6 NPPB CRP
46 posterior myocardial infarction 29.5 PLAT PIK3C2A
47 disseminated intravascular coagulation 29.4 PLAT PIK3C2A CRP
48 atrial heart septal defect 29.3 PLAT NPPB CRP
49 coronary heart disease 1 29.3 PLAT NPPB CRP
50 peripheral vascular disease 29.3 PLAT CRP

Comorbidity relations with Cardiogenic Shock via Phenotypic Disease Network (PDN): (show all 16)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Aortic Valve Disease 1
Cardiac Arrest Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Intermediate Coronary Syndrome Kidney Disease
Mitral Valve Disease Peripheral Vascular Disease
Respiratory Failure Third-Degree Atrioventricular Block
Tricuspid Valve Disease Ventricular Fibrillation, Paroxysmal Familial, 1

Graphical network of the top 20 diseases related to Cardiogenic Shock:



Diseases related to Cardiogenic Shock

Symptoms & Phenotypes for Cardiogenic Shock

Human phenotypes related to Cardiogenic Shock:

58 (show all 25)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 reduced consciousness/confusion 58 Frequent (79-30%)
2 dyspnea 58 Frequent (79-30%)
3 congestive heart failure 58 Frequent (79-30%)
4 myocardial infarction 58 Frequent (79-30%)
5 mitral regurgitation 58 Occasional (29-5%)
6 vertigo 58 Occasional (29-5%)
7 increased serum lactate 58 Occasional (29-5%)
8 metabolic acidosis 58 Occasional (29-5%)
9 hypoxemia 58 Frequent (79-30%)
10 hypotension 58 Very frequent (99-80%)
11 oliguria 58 Frequent (79-30%)
12 confusion 58 Occasional (29-5%)
13 coma 58 Very rare (<4-1%)
14 cardiac arrest 58 Frequent (79-30%)
15 left ventricular dysfunction 58 Very frequent (99-80%)
16 abnormal ekg 58 Very frequent (99-80%)
17 impaired myocardial contractility 58 Frequent (79-30%)
18 elevated serum creatinine 58 Occasional (29-5%)
19 low-output congestive heart failure 58 Very frequent (99-80%)
20 crackles 58 Frequent (79-30%)
21 right ventricular failure 58 Very rare (<4-1%)
22 st segment elevation 58 Occasional (29-5%)
23 elevated jugular venous pressure 58 Frequent (79-30%)
24 low pulse pressure 58 Frequent (79-30%)
25 increased pulmonary capillary wedge pressure 58 Frequent (79-30%)

UMLS symptoms related to Cardiogenic Shock:


syncope, shock without mention of trauma

Drugs & Therapeutics for Cardiogenic Shock

PubMed Health treatment related to Cardiogenic Shock: 62

Cardiogenic shock is life threatening and requires emergency medical treatment . The condition usually is diagnosed after a person has been admitted to a hospital for a heart attack . If the person isn't already in a hospital, emergency treatment can start as soon as medical personnel arrive. The first goal of emergency treatment for cardiogenic shock is to improve the flow of blood and oxygen to the body’s organs . Sometimes both the shock and its cause are treated at the same time. For example, doctors may quickly open a blocked blood vessel that's damaging the heart . Often, this can get the patient out of shock with little or no additional treatment .

Drugs for Cardiogenic Shock (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 208)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dalteparin Approved Phase 4 9005-49-6
2
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
3
Enoxaparin Approved Phase 4 9005-49-6 772
4
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
6
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
9
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
10
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
11
Abciximab Approved Phase 4 143653-53-6
12
Probucol Approved, Investigational Phase 4 23288-49-5 4912
13
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
14
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
15
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
16
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
17
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
18
Streptokinase Approved, Investigational Phase 4 9002-01-1
19
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
20
Atorvastatin Approved Phase 4 134523-00-5 60823
21
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
22
Dobutamine Approved Phase 4 34368-04-2 36811
23
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
24
Racepinephrine Approved Phase 4 329-65-7 838
25
Norepinephrine Approved Phase 4 51-41-2 439260
26
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
27
tannic acid Approved Phase 4 1401-55-4
28
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
29
Hydralazine Approved Phase 4 86-54-4 3637
30
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
31
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
32
AT-101 Approved, Investigational Phase 4 652-67-5, 90141-22-3 12597
33
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
34
Ticagrelor Approved Phase 4 274693-27-5 9871419
35
Cangrelor Approved Phase 4 163706-06-7 9854012
36
carbamide peroxide Approved Phase 4 124-43-6
37
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
38
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
39
Mycophenolic acid Approved Phase 4 24280-93-1 446541
40
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
41
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
42
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
43
Tenecteplase Approved Phase 4 191588-94-0
44
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
45 Anticoagulants Phase 4
46 Calcium, Dietary Phase 4
47 Hormones Phase 4
48 Hormone Antagonists Phase 4
49 Heparin, Low-Molecular-Weight Phase 4
50 Sodium Potassium Chloride Symporter Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 288)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock (ES-FISH) Unknown status NCT03437369 Phase 4 Ivabradine Oral Tablet
2 Safety and Efficacy of Thrombus Aspiration in Patients With ST-segment Elevation Myocardial Infarction (STEMI) Unknown status NCT02606435 Phase 4
3 Comparing a Diuretic Vascular Filling in the Initial Management of Acute Pulmonary Embolism With Right Ventricular Dysfunction Normotensive Unknown status NCT02531581 Phase 4 Furosemide;NaCl 9% isotonic
4 The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
5 Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism Unknown status NCT01956955 Phase 4 enoxaparin ,alteplase, unfractionated heparin
6 Prospective Randomized Multicenter Study Comparing Immediate Multivessel Revascularization by PCI Versus Culprit Lesion PCI With Staged Non-culprit Lesion Revascularization in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock Completed NCT01927549 Phase 4
7 Randomized Clinical Study of Extra-Corporal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction Completed NCT02544594 Phase 4
8 Optimizing the Use of Vasopressor After Coronary Reperfusion in Cardiogenic Shock Secondary to Myocardial Infarction. Pathophysiological Study Comparing the Efficacy and Cardio-circulatory Tolerability of Epinephrine and Norepinephrine Completed NCT01367743 Phase 4 epinephrine perfusion;norepinephrine perfusion
9 Randomized Clinical Study of Intraaortic Balloon Pump Use in Cardiogenic Shock Complicating Acute Myocardial Infarction Completed NCT00491036 Phase 4
10 Left Ventricular Assist Device (Impella LP 2.5) vs. Intraaortic Balloon Counterpulsation (IABP) in Patients With Cardiogenic Shock and Acute Coronary Syndromes Completed NCT00417378 Phase 4
11 Routine Upfront Abciximab Versus Standard Peri-Procedural Therapy in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock PRAGUE-7 Trial. Completed NCT00420030 Phase 4 Abciximab
12 Safety and Efficacy of Levosimendan in Patients With Acute Myocardial Infarction Complicated by Symptomatic Left Ventricular Failure. Completed NCT00324766 Phase 4 levosimendan;placebo,
13 Prospective, Randomized Trial of Rapamycin- and Zotarolimus-eluting Stents for the Reduction of Coronary Restenosis Completed NCT00598533 Phase 4
14 Thrombus Aspiration Before Standard Primary Angioplasty Improves Myocardial Reperfusion in Acute Myocardial Infarction. Completed NCT00257153 Phase 4
15 Intracoronary Stenting and Angiographic Results: ORSIRO Stents Versus Xience PRIME Stents Assessed by Optical Coherence Tomography Completed NCT01594736 Phase 4 ORSIRO
16 Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Plexus Block, a Randomized Controlled Study Completed NCT02630290 Phase 4 Ropivacaine;Ropivacaine + Dexmedetomidine
17 Pilot Randomized Clinical Trial Comparing the Efficacy of Two Different Hypothermia Temperatures for Treatment of Comatose Patients Recovered From an Out-of-hospital Cardiac Arrest Completed NCT01155622 Phase 4
18 ON Pump vs OFF Pump Myocardial Revascularization in High Risk Patients: a Randomized Study Completed NCT01290952 Phase 4
19 Clopidogrel Or Metoprolol in Myocardial Infarction Trial Completed NCT00222573 Phase 4 clopidogrel and metoprolol
20 Efficacy and Safety Evaluation of Recombinant Streptokinase and Urokinase in the Treatment of Pulmonary Embolism: A Multi-Center, Randomized Controlled Trial in China Completed NCT00968929 Phase 4 Recombinant Streptokinase;Urokinase
21 Pain, Agitation and Delirium Protocol in Ventilated Patients in the Duke CICU Completed NCT02903407 Phase 4 Midazolam;Propofol;Dexmedetomidine
22 A Randomised Trial on Early Stress Nuclear Scan for Patients Presented to the Emergency Department (ED) With Chest Pain But Non-diagnostic Electrocardiography-Acute Chest Pain Treatment and Evaluation (ACTION) Study Completed NCT00434564 Phase 4
23 CompariSon of Manual Aspiration With Rheolytic Thrombectomy in Patients Undergoing Primary PCI. The SMART-PCI Trial Completed NCT01281033 Phase 4
24 Comparison of Efficiency of High Dose Atorvastatin and Endothelial Progenitor-Capture Stents and Bare Metal Stents in Reduction of Neointimal Formation in Patients With Non ST-Segment Elevation Acute Coronary Syndromes Completed NCT00494247 Phase 4
25 Optical Coherence Tomography Assessment of Gender diVersity In Primary Angioplasty: The OCTAVIA Trial Completed NCT02577965 Phase 4
26 Early Effect Of Bezafibrate On Fibrinogen Levels, Inflammatory Response And Clinical Impact, In Patients With ST Elevation Acute Myocardial Infarction Completed NCT02291796 Phase 4 Bezafibrate
27 Evaluation of Late Clinical Events After Drug-eluting Versus Bare-metal Stents in Patients at Risk: BAsel Stent Kosten Effektivitäts Trial - PROspective Validation Examination Part II (BASKET-PROVE II) Completed NCT01166685 Phase 4
28 Early Intra-aortic Balloon Pump Placement in Acute Decompensated Heart Failure Complicated by Cardiogenic Shock: a Randomized Clinical Trial Recruiting NCT04369573 Phase 4
29 Effect of Ivabradine on Heart Rate and Hemodynamics in Patients With Stage D Heart Failure (HF)/Cardiogenic Shock on Dobutamine Treatment Recruiting NCT03387605 Phase 4 Ivabradine;Placebo
30 Prospective Comparison of ARNI to Alternate Oral Vasodilator Therapies to Determine the Hemodynamic Profile and Relative Tolerability of (ARNIs) in Patients With Decompensated Heart Failure and Low Cardiac Output Recruiting NCT04206865 Phase 4 Sacubitril-Valsartan;Standard Oral Vasodilators
31 Comparison of Milrinone Versus Dobutamine in a Heterogeneous Population of Critically Ill Patients Recruiting NCT03207165 Phase 4 Milrinone;Dobutamine
32 Cangrelor Versus Ticagrelor In Patients With Acute Myocardial Infarction Complicated With Initial Cardiogenic Shock Recruiting NCT03551964 Phase 4 Cangrelor;Ticagrelor
33 Impact of Early CRRT Intervention in Patients Receiving VA-ECMO Support on 30-day Mortality: A Randomized Controlled Trial Recruiting NCT03549923 Phase 4 Esmolol;Standard care
34 China Tongxinluo Study for Myocardial Protection in Patients With Acute Myocardial Infarction Recruiting NCT03792035 Phase 4 Tongxinluo;Placebos
35 Intracoronary Analysis of Cardiac Allograft Vasculopathy in Comparison to Coronary Artery Disease by Means of Optical Coherence Tomography Recruiting NCT02254668 Phase 4
36 Safety and Efficacy of Adding Dapagliflozin and Furosemide in Diabetic Patients (Type 2) With Decompensated Heart Failure With Reduced Ejection Fraction (HFrEF) Recruiting NCT04385589 Phase 4 Dapagliflozin;insulin
37 Pharmacokinetic/Pharmacodynamic Effects of add-on Antiplatelet Therapy With Parenteral Cangrelor as Compared to Standard Dual Antiplatelet Treatment in Patients With ST-elevation Myocardial Infarction Complicated by Out-of-hospital Cardiac Arrest and Treated With Targeted Temperature Management Recruiting NCT03273075 Phase 4 Cangrelor;Placebo;Prasugrel;Ticagrelor
38 Ivabradine in Stage D Heart Failure Patients on Chronic Inotropes: A Pilot Study Not yet recruiting NCT03631654 Phase 4 Ivabradine;Placebos
39 HEMolysis in a Percutaneous Axial Flow Left Ventricular Assist Device, Effects of Pentoxifylline in a Randomized Controlled Trial Not yet recruiting NCT04391231 Phase 4 Pentoxifylline Oral Product;Placebo
40 National Multicenter Randomized Trial, Comparing Two Treatments of Myocardial Infarction Complicated With Cardiogenic Shock: Standard Treatment vs Standard Treatment Plus ECLS (Extracorporeal Life Support) Terminated NCT00314847 Phase 4
41 A Randomized Comparative Effectiveness Study of Routine Versus Selective Use of Fractional Flow Reserve (FFR) to Guide Non-Emergent Percutaneous Coronary Intervention (PCI) Terminated NCT02000661 Phase 4
42 TRIANA: A Randomized Trial to Compare the Efficay and Safety of Thrombolysis With Primary Angioplasty as Initial Reperfusion Therapy in Older Patients (>= 75 Years Old) With Acute Myocardial Infarction Terminated NCT00257309 Phase 4 Tenecteplase + UFH (+ clopidogrel, since 01/97)
43 Efficacy of Levosimendan in the Critically Ill Patients With Unstable Hemodynamics (the LICI Study) - A Double Blind Randomized Pilot Study Unknown status NCT00093301 Phase 2, Phase 3 Levosimendan;Dobutamine
44 Adjunctive Mild Hypothermia Therapy to Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated With Shock: A Feasibility Study Unknown status NCT00846222 Phase 3
45 Norepinephrine vs Norepinephrine and Dobutamine in Cardiogenic Shock : a Randomised, Opened, Cross-over Study. Heart SHOCK-NORDOB Study Unknown status NCT03340779 Phase 3 Norepinephrine
46 Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation Unknown status NCT03206658 Phase 3 Spironolactone 25 mg;Placebo oral capsule
47 Impact of One Stage Compared With Multistaged PCI Complete Revascularization on Clinical Outcome in Multivessel NSTEMI Patients. Smile Trial Unknown status NCT01478984 Phase 3
48 Efficacy of Furosemide Versus Vascular Filling in Patients With Acute Myocardial Infarction With Right Ventricular Extension: A Multicentric Randomized Controlled Trial Unknown status NCT02905760 Phase 3 Furosemide;Placebo filling;Placebo furosemide;Vascular filling
49 Evaluation of N-acetylcystein on Biomarkers of Platelet Activation , Cardiac Necrosis and Coronary Reperfusion in Patients Undergoing Percutaneous Coronary Intervention Unknown status NCT01741207 Phase 3 N-acetylcystein
50 Impact of Intravenous Exenatide Versus Insulin on Quality of Life in Cardiac Surgery Patients: an Ancillary Study of the ExSTRESS Phase II/III Clinical Trial Unknown status NCT02432976 Phase 2, Phase 3 Exenatide;Insulin

Search NIH Clinical Center for Cardiogenic Shock

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Digitalis preparation
DIGITALIS,POWDERED
Digitoxin
Digoxin
Glucagon
Inamrinone
inamrinone lactate

Genetic Tests for Cardiogenic Shock

Anatomical Context for Cardiogenic Shock

MalaCards organs/tissues related to Cardiogenic Shock:

40
Heart, Kidney, Liver, Lung, Testes, Brain, Endothelial

Publications for Cardiogenic Shock

Articles related to Cardiogenic Shock:

(show top 50) (show all 11153)
# Title Authors PMID Year
1
Cardiac troponin I levels in acute pulmonary embolism. 61 54
20222345 2009
2
Impaired plasma B-type natriuretic peptide clearance in human septic shock. 61 54
18679125 2008
3
Excimer laser in myocardial infarction: a comparison between STEMI patients with established Q-wave versus patients with non-STEMI (non-Q). 61 54
17426922 2008
4
B-type natriuretic peptide and its molecular precursor in myocardial infarction complicated by cardiogenic shock. 61 54
17448415 2007
5
Time-to-reperfusion therapy influences outcome of patients with myocardial infarction subjected to facilitated PCI. 61 54
19758922 2005
6
Natriuretic peptides and E-selectin as predictors of acute deterioration in patients with inotrope-dependent heart failure. 61 54
15848333 2005
7
Plasma brain natriuretic peptide reflects left ventricular function during percutaneous cardiopulmonary support. 61 54
14726055 2004
8
Quantitative measurement of the novel human plasma protein, IHRP, by sandwich ELISA. 54 61
11256472 2001
9
Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. 61 54
10099909 1999
10
Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infarction (The second National Registry of Myocardial Infarction). 54 61
9708650 1998
11
[Factors predictive of early mortality after acute myocardial infarction]. 54 61
8953932 1996
12
Temporal trends in in-hospital complications of acute coronary syndromes: Insights from the nationwide AMIS Plus registry. 61
32305559 2020
13
Various Manifestations of 5-Fluorouracil Cardiotoxicity: A Multicenter Case Series and Review of Literature. 61
31925673 2020
14
The Effect of High Lactate Level on Mortality in Acute Heart Failure Patients With Reduced Ejection Fraction Without Cardiogenic Shock. 61
32048133 2020
15
Acute myocardial infarction-cardiogenic shock in patients with prior coronary artery bypass grafting: A 16-year national cohort analysis of temporal trends, management and outcomes. 61
32085862 2020
16
Acute myocardial infarction presenting with cardiogenic shock in patients with previous coronary artery bypass graft: neglected disease or end-stage condition? 61
32265063 2020
17
Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: Subanalysis from the CULPRIT-SHOCK trial. 61
32497906 2020
18
Association Between Arterial Carbon Dioxide Tension and Clinical Outcomes in Venoarterial Extracorporeal Membrane Oxygenation. 61
32574466 2020
19
Clinical trials of acute mechanical circulatory support in cardiogenic shock and high-risk percutaneous coronary intervention. 61
32487943 2020
20
Cardiogenic shock with resultant multiple organ dysfunction syndrome. 61
32558792 2020
21
Venoarterial extracorporeal membrane oxygenation for postcardiotomy cardiogenic shock-A six-year service evaluation. 61
31970800 2020
22
Is previous cardiac surgery a risk factor for open repair of acute type A aortic dissection? 61
31585754 2020
23
Coronary revascularization and circulatory support strategies in patients with myocardial infarction, multi-vessel coronary artery disease, and cardiogenic shock: Insights from an international survey. 61
32474205 2020
24
Extracorporeal membrane oxygenation in peripartum cardiomyopathy: A review of the ELSO Registry. 61
32321653 2020
25
Predictors for acute and chronic renal failure and survival in patients supported with veno-arterial extracorporeal membrane oxygenation. 61
31789108 2020
26
An unusual thrombus location in a Heartmate 3TM device with fatal outcome. 61
31814521 2020
27
Impact of interhospital transfer on clinical outcomes and costs of extracorporeal life support. 61
32507298 2020
28
Current results of left ventricular assist device therapy in France: the ASSIST-ICD registry. 61
32298439 2020
29
Risk factors of in-hospital mortality in adult postcardiotomy cardiogenic shock patients successfully weaned from venoarterial extracorporeal membrane oxygenation. 61
31854226 2020
30
Clinical utility of venoarterial-extracorporeal membrane oxygenation (VA-ECMO) in patients with drug-induced cardiogenic shock: a retrospective study of the Extracorporeal Life Support Organizations' ECMO case registry. 61
31617764 2020
31
How to Manage Temporary Mechanical Circulatory Support Devices in the Critical Care Setting: Translating Physiology to the Bedside. 61
32503752 2020
32
Serotonin Syndrome Following Terbutaline Administration in a Heart Transplant Patient on Multiple Inotropic Agents: A Case Report. 61
32560969 2020
33
Revascularization in cardiogenic shock. 61
32548775 2020
34
Inotropic agents in cardiogenic shock. 61
32496275 2020
35
Mechanical assist devices for acute cardiogenic shock. 61
32496607 2020
36
Kidney and liver dysfunction in cardiogenic shock. 61
32520812 2020
37
Decompressive hemicraniectomy for acute ischemic stroke in a patient implanted with a left ventricular assist device: a case report. 61
32522145 2020
38
Understanding Characteristics of Acute Brain Injury in Adult Extracorporeal Membrane Oxygenation: An Autopsy Study. 61
32102063 2020
39
A single healthcare experience with Impella RP. 61
32569445 2020
40
Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials. 61
32361851 2020
41
National prevalence, trends and outcomes of takotsubo syndrome in hospitalizations with prior history of mediastinal/intrathoracic cancer and radiation therapy. 61
32087939 2020
42
Infective endocarditis in the Netherlands: current epidemiological profile and mortality : An analysis based on partial ESC EORP collected data. 61
32504340 2020
43
Impact of atrial fibrillation in critically-ill patients admitted to a stepdown unit. 61
32535903 2020
44
Association of Vitamin D Deficiency with Profound Cardiogenic Shock in Patients Resuscitated From Sudden Cardiac Arrest. 61
31490356 2020
45
Managing Malperfusion Syndrome in Acute Type A Aortic Dissection with Previous Cardiac Surgery. 61
32569666 2020
46
Venoarterial Extracorporeal Membrane Oxygenation After Surgical Repair of Type A Aortic Dissection. 61
32305219 2020
47
The place of extracorporeal life support in cardiogenic shock. 61
32520813 2020
48
Why can flu be so deadly? An unusual case of cardiogenic shock. 61
31104304 2020
49
Survival following venoarterial extracorporeal membrane oxygenation in postcardiotomy cardiogenic shock adults. 61
32529901 2020
50
Demographics, Procedural Characteristics, and Clinical Outcomes When Cardiogenic Shock Precedes TAVR in the United States. 61
32499022 2020

Variations for Cardiogenic Shock

Expression for Cardiogenic Shock

Search GEO for disease gene expression data for Cardiogenic Shock.

Pathways for Cardiogenic Shock

GO Terms for Cardiogenic Shock

Biological processes related to Cardiogenic Shock according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet-derived growth factor receptor signaling pathway GO:0048008 8.62 PLAT PIK3C2A

Molecular functions related to Cardiogenic Shock according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 8.8 PLAT NPPB ADM

Sources for Cardiogenic Shock

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....